Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 6/20 | 0.71 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.66 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3676027 | 1.00 | PTGER4 (0.71) | PTGER4PTGER3PTGER2 | |
| SCHEMBL10210255 | 0.92 | PTGER4 (0.84) | PTGER4PTGER3PTGER2 | |
| SCHEMBL10210269 | 0.91 | PTGER4 (0.66) | PTGER4PTGER3PTGER2 | |
| SCHEMBL14270380 | 0.91 | PTGER4 (0.66) | PTGER4PTGER3PTGER2 | |
| SCHEMBL10210579 | 0.91 | PTGER4 (0.71) | PTGER4PTGER3PTGER2 | |
| SCHEMBL10210267 | 0.90 | PTGER4 (0.71) | PTGER4 | |
| SCHEMBL14270390 | 0.90 | PTGER4 (0.57) | PTGER4 | |
| SCHEMBL14270385 | 0.90 | PTGER4 (0.66) | PTGER4 | |
| SCHEMBL10203174 | 0.90 | PTGER4 (0.61) | PTGER4PTGER3PTGER2 | |
| SCHEMBL10210359 | 0.90 | PTGER4 (0.64) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682065-B2 | Left ventricular diastolic function improving agent | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-20 | — | — | US | claimed |
| US-20140179606-A1 | LEFT VENTRICULAR DIASTOLIC FUNCTION IMPROVING AGENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | claimed |
| EP-2740475-A1 | LEFT VENTRICULAR DIASTOLIC FUNCTION IMPROVING AGENT | ONO Pharmaceutical Co., Ltd. (JP) | 2014-06-11 | — | — | EP | claimed |
| US-8507545-B2 | Cytotoxic T cell activator comprising EP4 agonist | NATIONAL UNIVERSITY CORPORATION, HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE (JP) | 2013-08-13 | — | — | US | claimed |
| US-20100216689-A1 | CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | claimed |
| EP-2147672-A1 | CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST | Nat. University Corp. Hamamatsu University School of Medicine (JP) | 2010-01-27 | — | — | EP | claimed |
| US-20080234337-A1 | Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-25 | — | — | US | claimed |
| US-20080021021-A1 | Preventive And/Or Remedy For Lower Urinary Tract Diseases Containing Ep4 Agonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | claimed |
| EP-1782830-A1 | PREVENTIVE AND/OR REMEDY FOR LOWER URINARY TRACT DISEASES CONTAINING EP4 AGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-09 | — | — | EP | claimed |
| US-9682065-B2 | Left ventricular diastolic function improving agent | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| US-9682065-B2 | Left ventricular diastolic function improving agent | ONO PHARMACEUTICAL CO., LTD. (JP) | 2017-06-20 | — | — | US | disclosed |
| CN-103717219-B | Agent for improving diastolic function of left ventricle | 小野药品工业株式会社 | 2017-02-15 | — | — | CN | disclosed |
| US-20140179606-A1 | LEFT VENTRICULAR DIASTOLIC FUNCTION IMPROVING AGENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20140179606-A1 | LEFT VENTRICULAR DIASTOLIC FUNCTION IMPROVING AGENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-06-26 | — | — | US | disclosed |
| US-20100216689-A1 | CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-08-26 | — | — | US | disclosed |
| EP-2147672-A1 | CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST | Nat. University Corp. Hamamatsu University School of Medicine (JP) | 2010-01-27 | — | — | EP | disclosed |
| US-20080234337-A1 | Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-09-25 | — | — | US | disclosed |
| US-20080021021-A1 | Preventive And/Or Remedy For Lower Urinary Tract Diseases Containing Ep4 Agonist | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | US | disclosed |
| EP-1782830-A1 | PREVENTIVE AND/OR REMEDY FOR LOWER URINARY TRACT DISEASES CONTAINING EP4 AGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-09 | — | — | EP | disclosed |
| EP-1782829-A1 | PREVENTIVE AND/OR REMEDY FOR HYPERKALEMIA CONTAINING EP4 AGONIST | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234337-A1 | Preventive and/or Remedy for Hyperkalemia Containing Ep4 Agonist | KCNJ4, KCNK4, KCNA4 | PTGER4 86/4885PTGER3 297/4885PTGER2 333/4885 |
| US-20100216689-A1 | CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST | CD4, PTGER4, LTB4R | PTGER4 2/4885PTGER3 26/4885PTGER2 22/4885 |
| US-20080021021-A1 | Preventive And/Or Remedy For Lower Urinary Tract Diseases Containing Ep4 Agonist | PTGER4, PTGES3, CYSLTR1 | PTGER4 1/4885PTGER3 4/4885PTGER2 13/4885 |
| US-20140179606-A1 | LEFT VENTRICULAR DIASTOLIC FUNCTION IMPROVING AGENT | FABP3, TNNT2, TNNI3 | PTGER4 266/4885PTGER3 238/4885PTGER2 252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.